孟鲁司特钠联合布地奈德雾化吸入治疗对咳嗽变异性哮喘患者肺功能及相关血清免疫指标水平的影响

Effect of Montelukast Sodium Combined with Budesonide Inhalation on Pulmonary Function and Serum Immune Indexes in Patients with Cough Variant Asthma

目的:探讨孟鲁司特钠联合布地奈德雾化吸入治疗对咳嗽变异性哮喘患者肺功能及相关血清免疫指标水平的影响。方法:分析笔者所在医院2015年2月-2017年3月收治的咳嗽变异性哮喘患者60例,依据治疗措施不同进行分组,对照组30例和观察组30例。对照组采用布地奈德雾化吸入治疗,观察组采用孟鲁司特钠联合布地奈德雾化吸入治疗。观察两组咳嗽变异性哮喘患者治疗前后咳嗽症状积分、PEF/预计值、FEV1/FVC、Ig E、TNF-α、IL-4情况,观察两组患者临床疗效情况。结果:两组咳嗽变异性哮喘患者治疗前咳嗽症状积分、PEF/预计值、FEV1/FVC、Ig E、TNF-α、IL-4比较,差异均无统计学意义(P>0.05),治疗后对照组和观察组咳嗽症状积分(1.53±0.28)分和(0.67±0.13)分、Ig E(1 029.8±31.7)U/ml和(619.8±30.8)U/ml、TNF-α(830.4±35.8)ng/ml和(530.6±33.8)ng/ml、IL-4(83.4±12.3)ng/ml和(54.8±10.2)ng/ml,均低于治疗前(3.15±0.55)分和(3.12±0.52)分、(1 578.2±44.3)U/ml和(1 572.9±42.9)U/ml、(1 180.8±41.8)ng/ml和(1 182.4±43.5)ng/ml、(115.4±17.8)ng/ml和(117.8±16.8)ng/ml,PEF/预计值(85.4±6.0)%和(90.9±6.2)%、FEV1/FVC(84.7±5.0)%和(88.8±4.6)%,均高于治疗前(80.3±5.6)%和(80.0±5.9)%、(80.3±5.6)%和(80.0±5.9)%,观察组治疗后咳嗽症状积分、Ig E、TNF-α、IL-4均低于对照组,PEF/预计值、FEV1/FVC均高于对照组,观察组患者临床治疗总有效率(96.7%)高于对照组(66.7%),差异有统计学意义(P<0.05)。结论:孟鲁司特钠联合布地奈德雾化吸入治疗咳嗽变异性哮喘患者,临床症状、肺功能、血清免疫指标改善明显,疗效良好,值得临床推广应用。

Objective：To explore influence of lung function and relevant serum immune indicators for cough variant asthma patients by Montelukast combined with Budesonide Aerosol Inhalation treatment.Method：From February 2015 to March 2017,60 cases of cough variant asthma patients in our hospital were analyzed,who were divided into two group by different treatment method,the control group 30 cases and the detection group 30 cases.The control group took Budesonide Aerosol Inhalation treatment,the detection group took Montelukast combined with Budesonide Aerosol Inhalation treatment.The cough symptoms integral,PEF/predicted value,FEV1/FVC,Ig E,TNF-α,IL-4 of two group cough variant asthma patients before treatment and after treatment were detected,the clinical effects of two group cough variant asthma patients were detected.Result：The cough symptoms integral PEF/predicted value,FEV1/FVC,Ig E,TNF-α,IL-4 of two groups cough variant asthma patients before treatment were no difference（P〉0.05）,the cough symptoms integral（1.53±0.28）score and（0.67±0.13）score,Ig E（1 029.8±31.7）U/ml and（619.8±30.8）U/ml,TNF-α（830.4±35.8）ng/ml and（530.6±33.8）ng/ml,IL-4（83.4±12.3）ng/ml and（54.8±10.2）ng/ml of the control group and the detection group after treatment,they were lower than before treatment（3.15±0.55）scores and（3.12±0.52）scores,（1 578.2±44.3）U/ml and（1 572.9±42.9）U/ml,（1 180.8±41.8）ng/ml and（1 182.4±43.5）ng/ml,（115.4±17.8）ng/ml and（117.8±16.8）ng/ml,PEF/predicted value（85.4±6.0）% and（90.9±6.2）%,FEV1/FVC（84.7±5.0）% and（88.8±4.6）%,they were higher than before treatment（80.3±5.6）% and（80.0±5.9）%,（80.3±5.6）% and（80.0±5.9）%,the cough symptoms integral,Ig E,TNF-α,IL-4 of the detection group after treatment were lower than control group,PEF/predicted value、FEV1/FVC were higher control group, the difference were statistical significance（P〈0.05）.Conclusion：The cough variant asthma patients by Montelukast combined with Budesonide Aerosol Inhalation treatment,clinical symptoms,lung function,serum immunity index are improved obviously,the clinical effects is good,it is worth to be used.